Overview

Adjuvant Durvalumab for Esophageal Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Adjuvant Durvalumab vs Placebo for 1 year after complete resection of esophageal cancer following neoadjuvant CCRT.
Phase:
Phase 2
Details
Lead Sponsor:
Samsung Medical Center
Treatments:
Antibodies, Monoclonal
Durvalumab